Literature DB >> 9003385

The characterization of endosomal insulin degradation intermediates and their sequence of production.

P J Seabright1, G D Smith.   

Abstract

Insulin degradation within isolated rat liver endosomes was studied in vitro with the aid of three 125I-insulin isomers specifically labelled at tyrosine (A14, B16 and B26). Chloroquine and 1,10-phenanthroline were used to minimize insulin proteolysis during endosome preparation, whereas the manipulation of endosomal processing of insulin in vitro by Co2+ ions (to activate) and 1,10-phenanthroline (to inhibit) permitted the study of degradation intermediates and their time-dependent production. Structural and kinetic analysis of intermediates isolated from both intra- and extra-endosomal compartments allowed the determination of major cleavage sites and the probable sequence of proteolytic events. It was found that 125I-tyrosine is the ultimate labelled degradation product of all iodo-insulin isomers, suggesting that endosomal proteases are able to degrade insulin to the level of its constituent amino acids. 125I-tyrosine was also the only radiolabelled product able to cross the endosomal membrane. Intra-endosomal insulin degradation proceeds via two inter-related cleavage routes after metalloendoprotease cleavage of the B-chain. One pathway results from an initial cleavage in the centre region of the B-chain (B7-19), probably at B14-15, whereas the major route results from a cleavage at B24-25. B24-25 cleavage removes the B-chain C-terminal hexapeptide (B25-30), which is subsequently cleaved by an aminopeptidase activity to produce first the pentapeptide B26-30 and then 125I-tyrosine. The isolation of intact radiolabelled A-chain from the degradation of 125I-[A14]-insulin suggests that further degradation of proteolytic intermediates containing cleaved B-chain proceeds via interchain disulphide reduction. The A-chain is then processed by several cleavages, one of which occurs at A13-14.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9003385      PMCID: PMC1218020          DOI: 10.1042/bj3200947

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  30 in total

1.  In vivo association of [125I]-insulin with a cytosolic insulin-degrading enzyme: detection by covalent cross-linking and immunoprecipitation with a monoclonal antibody.

Authors:  J Hari; K Shii; R A Roth
Journal:  Endocrinology       Date:  1987-02       Impact factor: 4.736

2.  Effects of metalloendoprotease inhibitors on insulin binding, internalization and processing in adipocytes.

Authors:  A Jochen; P Berhanu
Journal:  Biochem Biophys Res Commun       Date:  1987-01-15       Impact factor: 3.575

3.  Characterization of insulin degradation by rat-liver low-density vesicles.

Authors:  R J Pease; G D Smith; T J Peters
Journal:  Eur J Biochem       Date:  1987-04-01

4.  Characterization of insulin uptake into subcellular fractions of perfused rat liver using two different iodinated tracers.

Authors:  J R Christensen; G D Smith; T J Peters
Journal:  Cell Biochem Funct       Date:  1985-01       Impact factor: 3.685

5.  Redistribution of 125I-insulin on the surface of rat hepatocytes as a function of dissociation time.

Authors:  J L Carpentier; M Fehlmann; E Van Obberghen; P Gorden; L Orci
Journal:  Diabetes       Date:  1985-10       Impact factor: 9.461

6.  Isolation and partial characterization of the rat liver ligandosome fraction.

Authors:  R J Pease; G A Sharp; G D Smith; T J Peters
Journal:  Biochim Biophys Acta       Date:  1984-07-11

7.  The major protein of GLUT4-containing vesicles, gp160, has aminopeptidase activity.

Authors:  K V Kandror; L Yu; P F Pilch
Journal:  J Biol Chem       Date:  1994-12-09       Impact factor: 5.157

8.  Receptor binding properties of monoiodotyrosyl insulin isomers purified by high performance liquid chromatography.

Authors:  B H Frank; D E Peavy; C S Hooker; W C Duckworth
Journal:  Diabetes       Date:  1983-08       Impact factor: 9.461

Review 9.  Comparative specificity of microbial proteinases.

Authors:  K Morihara
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1974

10.  Degradation of endocytosed insulin in rat liver is mediated by low-density vesicles.

Authors:  R J Pease; G D Smith; T J Peters
Journal:  Biochem J       Date:  1985-05-15       Impact factor: 3.857

View more
  6 in total

1.  Disorders of glucose metabolism: post mortem analyses in forensic cases--part II.

Authors:  Frank Musshoff; Cornelius Hess; Burkhard Madea
Journal:  Int J Legal Med       Date:  2010-10-07       Impact factor: 2.686

2.  Uptake and metabolic fate of [HisA8,HisB4,GluB10,HisB27]insulin in rat liver in vivo.

Authors:  F Authier; G M Di Guglielmo; G M Danielsen; J J Bergeron
Journal:  Biochem J       Date:  1998-06-01       Impact factor: 3.857

Review 3.  Targeting Insulin-Degrading Enzyme in Insulin Clearance.

Authors:  Malcolm A Leissring; Carlos M González-Casimiro; Beatriz Merino; Caitlin N Suire; Germán Perdomo
Journal:  Int J Mol Sci       Date:  2021-02-24       Impact factor: 5.923

4.  Novel covalently linked insulin dimer engineered to investigate the function of insulin dimerization.

Authors:  Tine N Vinther; Mathias Norrman; Holger M Strauss; Kasper Huus; Morten Schlein; Thomas Å Pedersen; Thomas Kjeldsen; Knud J Jensen; František Hubálek
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

Review 5.  Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.

Authors:  Carlos M González-Casimiro; Beatriz Merino; Elena Casanueva-Álvarez; Tamara Postigo-Casado; Patricia Cámara-Torres; Cristina M Fernández-Díaz; Malcolm A Leissring; Irene Cózar-Castellano; Germán Perdomo
Journal:  Biomedicines       Date:  2021-01-17

6.  Evolutionary Origin of Insulin-Degrading Enzyme and Its Subcellular Localization and Secretion Mechanism: A Study in Microglial Cells.

Authors:  Miriam Corraliza-Gómez; Concepción Lillo; Irene Cózar-Castellano; Eduardo Arranz; Diego Sanchez; Maria D Ganfornina
Journal:  Cells       Date:  2022-01-11       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.